Gland Pharma Limited (GLAND.BO)
INR 1762.35
(-0.09%)
INR 1762.35
(-0.09%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 56.41 Billion | 35.91 Billion | 43.84 Billion | 34.23 Billion | 25.71 Billion | 19.93 Billion |
| Cost of Revenue | 40.04 Billion | 16.85 Billion | 21.09 Billion | 14.91 Billion | 11.02 Billion | 8.57 Billion |
| Gross Profit | 16.37 Billion | 19.06 Billion | 22.74 Billion | 19.31 Billion | 14.69 Billion | 11.36 Billion |
| Operating Expenses | 3.86 Billion | 10.19 Billion | 8.74 Billion | 7.28 Billion | 6.07 Billion | 5.22 Billion |
| Selling, General and Administrative Expenses | 1.69 Billion | 755.64 Million | 711.41 Million | 529.64 Million | 310.27 Million | 227.41 Million |
| Research and Development Expenses | 320.32 Million | 403.77 Million | 426.56 Million | 321.99 Million | 228.75 Million | 207.17 Million |
| Other Expenses | 1.7 Billion | 10.53 Million | 15.99 Million | 82.77 Million | 9.78 Million | 5.76 Million |
| Cost and Expenses | 46.5 Billion | 27.05 Billion | 29.83 Billion | 22.19 Billion | 17.09 Billion | 13.79 Billion |
| Operating Income | 9.9 Billion | 8.88 Billion | 14.03 Billion | 11.78 Billion | 8.05 Billion | 5.73 Billion |
| Interest Expense | 262 Million | 62.87 Million | 34.02 Million | 29.11 Million | 62.51 Million | 26.17 Million |
| Income Tax Expense | 3.6 Billion | 2.73 Billion | 4.06 Billion | 3.37 Billion | 2.2 Billion | 2.34 Billion |
| Earnings before Tax | 11.32 Billion | 10.54 Billion | 16.18 Billion | 13.34 Billion | 9.92 Billion | 6.86 Billion |
| Net Income | 7.72 Billion | 7.81 Billion | 12.11 Billion | 9.96 Billion | 7.72 Billion | 4.51 Billion |
| Earnings Per Share Basic | 46.90 | 47.44 | 73.81 | 63.07 | 49.88 | 27.67 |
| Earnings Per Share Diluted | 46.89 | 47.43 | 73.64 | 62.99 | 49.88 | 27.67 |
| Weighted Average Shares Outstanding | 164.7 Million | 164.63 Million | 164.15 Million | 158.07 Million | 154.94 Million | 163.28 Million |
| Weighted Average Shares Outstanding (Diluted) | 164.73 Million | 164.67 Million | 164.53 Million | 158.27 Million | 154.94 Million | 163.28 Million |
| Gross Margin | 0.29 | 0.53 | 0.52 | 0.56 | 0.57 | 0.57 |
| EBIT Margin | 0.27 | 0.35 | 0.39 | 0.42 | 0.42 | 0.39 |
| Profit Margin | 0.14 | 0.22 | 0.28 | 0.29 | 0.30 | 0.23 |
| EBITDA | 15.03 Billion | 12.08 Billion | 17.34 Billion | 14.37 Billion | 10.94 Billion | 7.72 Billion |
| Earnings Before Tax Margin | 0.18 | 0.25 | 0.32 | 0.34 | 0.31 | 0.29 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 14.05 Billion | 14.01 Billion | 56.64 Billion | 15.37 Billion | 15.45 Billion | 13.73 Billion |
| Cost of Revenue | 10.44 Billion | 10.58 Billion | 40.04 Billion | 11.01 Billion | 5.99 Billion | 5.21 Billion |
| Gross Profit | 3.61 Billion | 3.43 Billion | 16.6 Billion | 4.35 Billion | 9.45 Billion | 8.51 Billion |
| Operating Expenses | 1.58 Billion | 1.71 Billion | 6.71 Billion | 1.69 Billion | 6.94 Billion | 6.09 Billion |
| Selling, General and Administrative Expenses | 1.08 Billion | 1.22 Billion | - | 1.26 Billion | 1.27 Billion | 1.29 Billion |
| Research and Development Expenses | 493 Million | 489 Million | - | 436 Million | 530 Million | 351 Million |
| Other Expenses | - | 514.26 Million | 1.7 Billion | 421.47 Million | 373.91 Million | 531.55 Million |
| Cost and Expenses | 12.02 Billion | 12.29 Billion | 46.76 Billion | 12.71 Billion | 12.94 Billion | 11.3 Billion |
| Operating Income | 2.03 Billion | 1.72 Billion | 9.88 Billion | 2.66 Billion | 2.88 Billion | 2.42 Billion |
| Interest Expense | 61.12 Million | 56.16 Million | 262 Million | 99.58 Million | 52.81 Million | 60.46 Million |
| Income Tax Expense | 932.46 Million | 744.84 Million | 3.6 Billion | 1.05 Billion | 913.02 Million | 958.06 Million |
| Earnings before Tax | 2.56 Billion | 2.18 Billion | 11.32 Billion | 2.98 Billion | 2.83 Billion | 2.89 Billion |
| Net Income | 1.63 Billion | 1.43 Billion | 7.72 Billion | 1.92 Billion | 1.91 Billion | 1.94 Billion |
| Earnings Per Share Basic | 9.93 | 8.73 | - | 11.68 | 11.65 | 11.78 |
| Earnings Per Share Diluted | 9.93 | 8.73 | - | 11.68 | 11.65 | 11.78 |
| Weighted Average Shares Outstanding | 164.75 Million | 164.75 Million | 164.7 Million | 164.7 Million | 164.7 Million | 164.7 Million |
| Weighted Average Shares Outstanding (Diluted) | 164.75 Million | 164.75 Million | 164.73 Million | 164.7 Million | 164.7 Million | 164.7 Million |
| Gross Margin | 0.26 | 0.25 | 0.29 | 0.28 | 0.61 | 0.62 |
| EBIT Margin | 0.25 | 0.19 | - | 0.23 | 0.25 | 0.27 |
| Profit Margin | 0.12 | 0.10 | 0.14 | 0.13 | 0.12 | 0.14 |
| EBITDA | 3.56 Billion | 2.64 Billion | - | 3.58 Billion | 3.93 Billion | 3.77 Billion |
| Earnings Before Tax Margin | 0.14 | 0.12 | 0.17 | 0.17 | 0.19 | 0.18 |
5076
CONCORDBIO
KWI
HBMN
OCGPF
LTF